Increasing Incidence of Celiac Disease is Contributing to the Market Growth

Published: Feb 2025

The global celiac disease drug market is anticipated to grow significantly during the forecast period (2024-2031). The market growth is driven by the development of several anti-inflammatory medications and therapeutic vaccinations that will replace or enhance a gluten-free diet. Additionally, government initiatives for the treatment of celiac disease are contributing to the market growth. Furthermore, significant R&D investments for the treatment of celiac disease are propelling the market. The global celiac disease market is segmented by treatment type (vitamins and dietary (gluten-free) supplements, steroids and immunosuppressive drugs, and therapeutic vaccines), by diagnostic type (serologic test, genetic testing, and small-bowel biopsy) by end-user (hospitals and diagnostics centers, and research institutes), and geography (North America, Europe, Asia-Pacific, and the Rest of the World).

North America is anticipated to dominate the market, which is attributed to the rising prevalence of the condition in the region. Additionally, the growing focus of the market players to develop novel therapeutics is driving the market. Asia-Pacific is anticipated to exhibit significant growth during the forecast period, owing to the growing healthcare infrastructure high government spending, and rising patient awareness. 

The major companies serving the global celiac disease drug market include Abbott Laboratories, Eli Lilly & Co, Novartis AG, Johnson & Johnson, BioLineRx Ltd., Amgen Inc., Siemens AG, and Bayer AG among others. The market players are contributing significantly to the market growth by adopting various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new project launches significantly aiding the market expansion. 

Recent Developments

  • In September 2024, Barinthus Biotherapeutics plc announced the initiation of its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. It is a randomized, placebo-controlled clinical trial, including a controlled gluten challenge, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTP-1000.
  • In May 2023, Topas Therapeutics launched a Phase 2a clinical study (NCT05660109) evaluating the safety, tolerability, and pharmacodynamics of TPM502 in patients with celiac disease. It is developed using Topas Particle Conjugates (TPCs) nanotechnology and is a mixture of nanoparticles carrying gluten-specific antigenic peptides comprising the major gluten epitopes for HLA-DQ2.5 present in the majority of celiac disease patients.  

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/celiac-disease-drug-market